To combine the old with the new we will welcome Dr. Julia Elvin, senior associate medical director and senior pathologist of Foundation Medicine, Inc., as she discusses NGS Technology - Come join us! The pre-program reception (with food) will begin at 5:30p, with the talk starting promptly at 6:30pm.
For generations, pathologists have been critical members of the cancer care team, using their keen observational skills, deep knowledge of morphological patterns, and ability to leverage the latest laboratory techniques to provide key predictive and prognostic information. Today, our field is rapidly evolving as massively parallel (next-generation) sequencing (NGS) is applied to cancer specimens, allowing us to detect genetic variants across the entire genome and to assign a molecular profile in addition to a traditional morphologic diagnosis. By applying comprehensive genomic profiling data to patient care, pathologists now are key participants in the search for potential therapy targets for patients with surgically incurable, relapsed and refractory disease. We will look at how NGS technology is being applied to routine clinical FFPE tumor samples and circulating tumor DNA from “liquid biopsies”. Experiences gained by testing of approximately 100,000 clinical tumor specimens will be presented, including the differential ability of specific approaches to detect different classes of individual genomic alterations (including base substitutions, short insertions/deletions, fusions and translocations, amplifications and homozygous deletions), observations of broader genomic patterns (including microsatellite instability status and tumor mutation burden), and the impact of AP lab tissue processing has on the validity of genomic results. Personalization of individual patient therapy and revolutionary clinical trial designs are not dreams for the future – they are realities today.
*No CME credits will be awarded for this lecture
If you have any questions please email email@example.com